Interview: CrystalGenomics, First Korean Bioventure To ‘Go All The Way’

After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.